These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 15949966)

  • 1. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 2. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias.
    Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A
    Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
    Wong KK; Alty JE; Goy AG; Raghav S; Reutens DC; Kempster PA
    Mov Disord; 2011 Jul; 26(8):1552-5. PubMed ID: 21538524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Stathis P; Konitsiotis S; Tagaris G; Peterson D;
    Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

  • 8. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 9. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

  • 10. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease.
    Prashantha DK; Pal PK
    Parkinsonism Relat Disord; 2009 Nov; 15(9):718-9. PubMed ID: 19157953
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
    Vidal EI; Fukushima FB; Valle AP; Villas Boas PJ
    J Am Geriatr Soc; 2013 Jan; 61(1):170-2. PubMed ID: 23311565
    [No Abstract]   [Full Text] [Related]  

  • 14. Levetiracetam in L-dopa-induced dyskinesia.
    Meco G; Fabrizio E; Epifanio A; Di Raimondo G; Vanacore N; Morgante L
    Clin Neuropharmacol; 2005; 28(2):102-3. PubMed ID: 15795556
    [No Abstract]   [Full Text] [Related]  

  • 15. Ropinirole as compared with levodopa in Parkinson's disease.
    Weiner WJ; Factor SA
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001687
    [No Abstract]   [Full Text] [Related]  

  • 16. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ropinirole as compared with levodopa in Parkinson's disease.
    Frucht S
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001686
    [No Abstract]   [Full Text] [Related]  

  • 18. Ropinirole as compared with levodopa in Parkinson's disease.
    Yamamoto T
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001685
    [No Abstract]   [Full Text] [Related]  

  • 19. Ropinirole as compared with levodopa in Parkinson's disease.
    Hiner BC; Earnhart M
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
    [No Abstract]   [Full Text] [Related]  

  • 20. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.